Clinical Trials

3-D Matrix is selling its approved hemostatic agent PuraStat®  in Europe, Latin America and Southeast Asia and preparing investigational studies for FDA approval. In the United States, 3-D Matrix has successfully completed a pilot study to use PuraMatrix®  as a dental bone void filler. In Japan 3-D Matrix is currently completing trials for various clinical applications.

 

PuraMatrix® is a platform technology that can fulfill numerous clinical indications and therapeutic needs.

syringe-with-hand

Hemostasis

PuraStat® has completed a successful clinical trial in Japan.  A clinical trial is being planned in the United States for PMA approval, and in Europe as post-marketing clinical follow-up studies

News

Find out the most recent developments at 3-D Matrix

Learn More

Collaborations

Learn how PuraMatrix® can enhance your technology

Learn More

Publications

Review the strong body of literature utilizing PuraMatrix®

Learn More

This website is not intended for French healthcare professionals.

If you are a French healthcare professional, please contact your sales representative for any information.


Ce site internet n’est pas destiné aux professionnels de santé française.

Si vous êtes un professionnel de santé français, merci de contacter votre contact local pour toutes demandes d’informations.

Continue